InvestSMART

Paradigm Biopharmaceuticals Limited (ASX:PAR)

ALERT: Price-sensitive ASX Announcement for PAR
Current share price for PAR : $0.155 -0.125 (-44.64%)+
Announcement
Release
29 Aug 2025 1:32PM
Price at Release
$0.280
Full Release
download
Summary
Paradigm Biopharmaceuticals Limited's 2025 Annual Report and Appendix 4E indicate a challenging financial year with a significant reduction in losses compared to the previous year. The company reported a loss after tax of AUD 18.77 million for the year ending 30 June 2025, a substantial decrease from the AUD 58.73 million loss in 2024. Revenue for 2025 was reported at AUD 7.1 million, primarily driven by research and development tax incentives and other income. The company's main focus remains on its global Phase 3 program for Zilosul® in knee osteoarthritis, with other assets like the respiratory program remaining strategic for future development. The company received AUD 6.3 million in R&D tax incentives and saw a cash outflow from operations of AUD 15.99 million. The report also highlights the issuance of new shares, raising AUD 16 million, and adjustments in financial statements from previous errors. Future strategies include the acquisition of Proteobioactives Pty Ltd to strengthen their position in the pharmaceutical industry.
Key Points
  • Loss after tax: AUD 18.77 million for 2025.
  • Revenue: AUD 7.1 million primarily from R&D tax incentives.
  • Focus on Phase 3 program for Zilosul® in knee osteoarthritis.
  • R&D tax incentives received: AUD 6.3 million.
  • Cash outflow from operations: AUD 15.99 million.
  • New share issuance raised AUD 16 million.
  • Acquisition of Proteobioactives Pty Ltd planned.
  • Financial restatements corrected previous errors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.